Avenue Therapeutics (ATXI) Q3 2024 earnings summary

Executive summary

• Focused on developing therapies for neurologic diseases, with lead candidates AJ201 (SBMA), IV tramadol (post-operative pain), and BAER-101 (epilepsy/panic disorders); advanced AJ201 clinical trial with topline data expected around year-end 2024.

• Progressed BAER-101 and IV tramadol programs, both pending further financing for next clinical phases.

• Net loss for the nine months ended September 30, 2024 was $10.1 million, down from $11.1 million in the prior year period.

• Accumulated deficit reached $101.0 million as of September 30, 2024.

• No revenue generated; operations funded primarily through equity offerings and warrant exercises.

Financial highlights

• Cash and cash equivalents were $2.6 million at September 30, 2024, up from $1.8 million at December 31, 2023, but down from $4.9 million at June 30, 2024.

• Research and development expenses rose to $6.1 million for the nine months ended September 30, 2024, with Q3 2024 R&D expenses at $2.3 million.

• General and administrative expenses increased to $3.6 million for the nine months ended September 30, 2024, but Q3 2024 G&A expenses were $0.8 million, down from $1.2 million in Q3 2023.

• Net cash used in operating activities was $8.3 million for the nine months ended September 30, 2024.

• Net cash provided by financing activities was $9.1 million, primarily from warrant exercises and ATM sales.

Outlook and guidance

• Expects continued operating losses and increased expenses as product development progresses.

• Additional financing will be required to fund operations beyond the first half of 2025.

• Topline data from the AJ201 Phase 1b/2a trial anticipated around year-end 2024.

• BAER-101 Phase 2a trial and IV tramadol Phase 3 safety study planned, contingent on additional financing or partnerships.